Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr785 Inhibitors

Olr785 inhibitors represent a fascinating class of chemical compounds that interact with the Olr785 receptor, a type of olfactory receptor found within the sensory epithelium of the nasal cavity. These receptors are part of a large family of G protein-coupled receptors (GPCRs) that play a crucial role in the detection of odor molecules. The inhibition of Olr785 can modulate the receptor's activity, thereby influencing the signal transduction pathways that are initiated when an odorant binds to the receptor. This interaction involves a complex interplay of molecular recognition and subsequent conformational changes in the receptor structure, which ultimately affects the receptor's ability to activate downstream signaling cascades. Understanding the precise mechanisms of Olr785 inhibition requires a detailed exploration of both the structural aspects of the receptor and the specific binding characteristics of the inhibitors.

Chemically, Olr785 inhibitors are diverse in their structure, encompassing a range of molecular frameworks that can interact with the receptor's active site. These inhibitors can be small organic molecules, peptides, or even larger biopolymers, each with distinct modes of binding and inhibition. Structural studies, often utilizing techniques like X-ray crystallography or cryo-electron microscopy, have revealed the key binding motifs and conformational states of the receptor when bound to these inhibitors. Additionally, computational methods, such as molecular docking and dynamic simulations, provide insights into the dynamic behavior of these complexes and help in elucidating the thermodynamic and kinetic properties of the inhibition process. This deepened understanding of Olr785 inhibitors not only sheds light on the fundamental principles of olfactory receptor function but also contributes to broader knowledge in the field of chemosensory signaling.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

Inhibits CDK4/6, potentially interrupting cell cycle progression and proliferation.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

A MEK inhibitor, might modulate MAPK/ERK signaling affecting cell growth.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Targets EGFR and HER2, could influence epidermal growth factor signaling.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor, could affect protein degradation and cell signaling.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

A BCR-ABL inhibitor, could modulate leukemia cell proliferation and survival pathways.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

Targets EGFR, potentially influencing non-small cell lung cancer signaling pathways.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

BRAF inhibitor, could impact cell growth and differentiation in melanoma.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Targets BTK, potentially modulating B-cell receptor signaling in leukemia and lymphoma.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Inhibits multiple tyrosine kinases, could affect cell growth and proliferation.